Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03503292 · ClinicalTrials.gov registry record · Phase 4
Pharmacogenomics and Post-Operative Nausea and Vomiting
A Phase 4 study of Postoperative Nausea, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 92
- Enrollment target
- 1
- Study location
NCT03503292 is a Phase 4 study of Postoperative Nausea that has completed, run by Mayo Clinic. The registered enrollment target is 92 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03503292, a Phase 4 study of Postoperative Nausea, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 92 participants
- Enrollment target
- 1
- Study location
Study Summary
The Researchers overall goal is to evaluate the benefit and utility of preemptive genotypic data to guide post-operative nausea and vomiting treatment in the bariatric surgical population. The hypothesis is that using genotypic variation in CYP2D6 to select the appropriate 5HT3 serotonin receptor antagonist to treat PONV will decrease rates of PONV in the bariatric surgical population.
Conditions Studied
Interventions
- DRUG Ondansetron
- DRUG Granisetron
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2018-05-02 |
| Est. Completion | 2019-12-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03503292
The ClinicalTrials.gov registry entry for NCT03503292 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Postoperative Nausea appearing as the primary indexed condition, and to 2 interventions - of which Ondansetron is the first listed.
NCT03503292 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT03503292 about?
NCT03503292 is a clinical study titled "Pharmacogenomics and Post-Operative Nausea and Vomiting". The Researchers overall goal is to evaluate the benefit and utility of preemptive genotypic data to guide post-operative nausea and vomiting treatment in the bariatric surgical population. The hypothesis is that using genotypic variation in CYP2D6 to select the appropriate 5HT3 serotonin receptor an...
What is the current status of trial NCT03503292?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 92 participants. The study started on 2018-05-02. Estimated completion is 2019-12-30.
What conditions does trial NCT03503292 study?
This clinical trial studies the following conditions: Postoperative Nausea.
What interventions are being tested in trial NCT03503292?
The interventions under investigation include: Ondansetron (DRUG), Granisetron (DRUG).
Who is sponsoring clinical trial NCT03503292?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03503292 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Postoperative Nausea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.